CMV outcomes in seropositive recipients undergoing UCBT by prevention strategy (n = 72)
| Outcome . | Intensive, n = 43 n (%) . | Standard, n = 29 n (%) . | Unadjusted HR (95% CI) . | P . | Adjusted HR (95% CI)* . | P . |
|---|---|---|---|---|---|---|
| CMV reactivation | 26 (60) | 29 (100) | 0.27 (0.15-0.47) | < .001 | 0.27 (0.15-0.48) | < .001 |
| Timing† | ||||||
| Early/pre-engraftment | 15 (58) | 25 (86) | 0.26 (0.14-0.50) | < .001 | 0.25 (0.13-0.49) | < .001 |
| Late/postengraftment | 11 (42) | 4 (14) | 0.29 (0.09-0.93) | .038 | 0.39 (0.11-1.35) | .14 |
| Complications | ||||||
| High-level viremia‡ | 3 (7) | 24 (83) | 0.05 (0.01-0.16) | < .001 | 0.04 (0.01-0.15) | < .001 |
| Resistant CMV | 1 (2) | 3 (10) | – | .30§ | ||
| CMV disease | 2 (5) | 8 (28) | 0.19 (0.04-0.91) | .038 | 0.11 (0.02-0.53)‖ | .006‖ |
| CMV-associated death | 0 (0) | 3 (10) | – | .06§ |
| Outcome . | Intensive, n = 43 n (%) . | Standard, n = 29 n (%) . | Unadjusted HR (95% CI) . | P . | Adjusted HR (95% CI)* . | P . |
|---|---|---|---|---|---|---|
| CMV reactivation | 26 (60) | 29 (100) | 0.27 (0.15-0.47) | < .001 | 0.27 (0.15-0.48) | < .001 |
| Timing† | ||||||
| Early/pre-engraftment | 15 (58) | 25 (86) | 0.26 (0.14-0.50) | < .001 | 0.25 (0.13-0.49) | < .001 |
| Late/postengraftment | 11 (42) | 4 (14) | 0.29 (0.09-0.93) | .038 | 0.39 (0.11-1.35) | .14 |
| Complications | ||||||
| High-level viremia‡ | 3 (7) | 24 (83) | 0.05 (0.01-0.16) | < .001 | 0.04 (0.01-0.15) | < .001 |
| Resistant CMV | 1 (2) | 3 (10) | – | .30§ | ||
| CMV disease | 2 (5) | 8 (28) | 0.19 (0.04-0.91) | .038 | 0.11 (0.02-0.53)‖ | .006‖ |
| CMV-associated death | 0 (0) | 3 (10) | – | .06§ |
CI indicates confidence interval; HR, hazard ratio; and UCBT, umbilical cord blood transplantation.
Multivariable model includes myeloablative vs nonmyeloablative conditioning, number of donor grafts, and GVHD (grade ≥ II, and time-dependent covariate) except where indicated.
Only patients who reactivated, early ≤ 30 days after transplantation and late > 30-100 days after transplantation.
High-level viremia is a PCR value ≥ 1000 copies at any point of time in the first 100 days after transplantation.
Calculated by the use of the Fisher exact probability test.
Adjusted only for acute GHVD in the multivariable model.